HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.

ABSTRACT: Limited access to HIV drug resistance testing in low- and middle-income countries impedes clinical decision-making at the individual patient level. An efficient protocol to address this issue must be established to minimize negative therapeutic outcomes for HIV-1-infected individuals in such settings. This is an observational study to ascertain the potential of newer genomic sequencing platforms, such as the Illumina MiSeq instrument, to provide accurate HIV drug resistance genotypes for hundreds of samples simultaneously. Plasma samples were collected from Canadian patients during routine drug resistance testing (n = 759) and from a Ugandan study cohort (n = 349). Amplicons spanning HIV reverse transcriptase codons 90 to 234 were sequenced with both MiSeq sequencing and conventional Sange

SUBMITTER: Lapointe HR 

PROVIDER: S-EPMC4604392 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature